Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-0,96
KB-0,82
PKN65,3165,340,37
Msft327,26327,290,61
Nokia3,77353,77750,53
IBM135,92135,951,11
Mercedes-Benz Group AG72,7872,8-0,33
PFE39,2439,250,43
09.06.2023 16:56:57
Indexy online
AD Index online
select
AD Index online
 

  • 09.06.2023 16:56:53
Exelixis (EXEL.O, NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
19,31 -0,21 -0,04 1 783 920
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 09.06.2023
Popis společnosti
Obecné informace
Název společnostiExelixis Inc
TickerEXEL
Kmenové akcie:Ordinary Shares
RICEXEL.O
ISIN-
Poslední známé roční výsledky31.12.2022
Poslední známé čtvrtletní výsledky31.03.2023
Počet zaměstnanců k 31.12.2022 1 223
Akcie v oběhu k 01.05.2023 325 636 738
MěnaUSD
Konstituent indexůS&P 400 Mid Cap
Kontaktní informace
Ulice1851 Harbor Bay Parkway
MěstoALAMEDA
PSČ94502
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 508 377 000
Fax16508378300

Business Summary: Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has four products, including its flagship molecule, cabozantinib, which is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company's (BMS) OPDIVO (nivolumab), for hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.
Financial Summary: BRIEF: For the 13 weeks ended 31 March 2023, Exelixis Inc revenues increased 15% to $408.8M. Net income decreased 42% to $40M. Revenues reflect CABOMETYX segment increase of 19% to $361.8M, License revenues segment increase of 21% to $29.8M, U.S segment increase of 17% to $367.4M, Japan segment increase of 6% to $7.8M. Net income was offset by Other Research and development increase of 56% to $231M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICSMedicinal and Botanical Manufacturing
NAICSIn-Vitro Diagnostic Substance Manufacturing
NAICSBiological Product (except Diagnostic) Manufacturing
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in Biotechnology
NAICS2007Medicinal & Botanical Mfg
NAICS2007In-Vitro Diagnostic Substance Mfg
NAICS2007Biological Product (exc Diagnostic) Mfg
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Medicinal and Botanical Manufacturing
NAICS1997InVitro Diagnostic Substance Manufacturing
NAICS1997Biological Product (except Diagnostic) Manufacturing
SICCommercial Physical Research
SICPharmaceutical Preparations
SICCommercial Physical Research
SICMedicinals And Botanicals
SICDiagnostic Substances
SICBiological Prod's Not Diagnostic



  • Poslední aktualizace: 09.06.2023
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorMichael Morrissey6215.07.2010
Chief Financial Officer, Executive Vice PresidentChristopher Senner5515.07.201515.07.2015
Executive Vice President - Discovery and Translational Research, Chief Scientific OfficerDana Aftab-15.12.202215.12.2022
Executive Vice President, General Counsel, SecretaryJeffrey Hessekiel5310.02.2014
Executive Vice President - Product Development and Medical Affairs, Chief Medical OfficerVicki Goodman5204.01.202204.01.2022
Executive Vice President - CommercialPatrick Haley46
Executive Vice President - Scientific StrategyPeter Lamb6115.12.2022